People · Operator
Named in public records as an officer, director or promoter · active 2008–2016 · Biotechnology, Pharmaceuticals, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Minerva Neurosciences, Inc. | — | Biotechnology | Series B | $52.0M | $219.4M | 2015 |
| Aegerion Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $48.7M | $622.8M | 2008 |
| Normoxys, Inc. | — | Biotechnology | Series B | $25.3M | $23.8M | 2009 |
| LinguaFlex, Inc. | — | Other Health Care | Series B | $23.8M | $79.8M | 2009 |
Michele Ollier at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michele Ollier on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Francesco De Rubertis | 2 | 4 |
| Remy Luthringer | 2 | 2 |
| Mark Levine | 1 | 9 |
| David Clark | 1 | 8 |
| Timothy Langloss | 1 | 7 |
| David Scheer | 1 | 6 |
| Jason Fisherman | 1 | 5 |
| John Miclot | 1 | 5 |
| Marc Beer | 1 | 4 |
| William Doyle | 1 | 4 |
| David Arkowitz | 1 | 3 |
| Jan Van Heek | 1 | 2 |
| Christine Pellizzari | 1 | 2 |
| Martin Tolar | 1 | 2 |
| Jean-Pierre Garnier | 1 | 2 |
| David Kupfer | 1 | 2 |
| Ira Sanders | 1 | 2 |
| Fred Ahlholm | 1 | 1 |
| Geoff Race | 1 | 1 |
| Nico Vandervelpen | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.